About Probable palmitoyltransferase ZDHHC11B
Probable palmitoyltransferase ZDHHC11B (ZDHHC11B) is a protein
from Homo sapiens identified by UniProt accession
P0C7U3, 371 residues long.
MolForge cross-references it against 0 known binders and
25 disease associations.
Target properties
| Protein name | Probable palmitoyltransferase ZDHHC11B |
|---|
| UniProt accession | P0C7U3 |
|---|
| Gene | ZDHHC11B |
|---|
| Organism | Homo sapiens |
|---|
| Length | 371 residues |
|---|
| Molecular weight | — |
|---|
| EC numbers | — |
|---|
| Target class | UNCLASSIFIED |
|---|
| Subcellular location | — |
|---|
| Keywords | — |
|---|
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
|---|
| Druggability score | — |
|---|
| Pocket score | — |
|---|
| Max clinical phase | — |
|---|
Disease associations (25)
Diseases linked to this target (Open Targets).
- Red cell distribution width · score 0.39
- FEV/FVC ratio · score 0.35
- lung adenocarcinoma · score 0.07
- deafness · score 0.06
- Myopia · score 0.06
- age at onset · score 0.06
- snoring measurement · score 0.05
- benign adult familial myoclonic epilepsy · score 0.04
- mean corpuscular hemoglobin concentration · score 0.03
- glomerular filtration rate · score 0.02
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
|---|
| AF-P0C7U3-F1 | alphafold | PREDICTED | 78.69 | — |
Amino-acid sequence (371 residues)
MDTRSGSQCS VTPEAIRNNE ELVLPPRISR VNGWSLPLHY FRVVTWAVFV GLSLATFRIF IPLLPHSWKY IAYVVTGGIF SFHLVVHLIA SCIDPADSNV RLMKNYSQPM PLFDRSKHAH VIQNQFCHLC KVTVNKKTKH CISCNKCVSG FDHHCKWINN CVGSRNYWFF FSTVASATAG MLCLIAILLY VLVQYLVNPR VLRTDPRYED VKNMNTWLLF LPLFPVQVQT LIVVIIRMLV LLLDLLGLVQ LGQLLIFHIY LKAKKMTTFE YLINTRKEES SKHQAVRKDP YVQMDKGFLQ QGAGALGSSA QGVKAKSSLL IYKCPCHFCT SVNQDGDSKA QEADDAPSTS TLGLQQETTE PMKTDSAESE D
Explore Probable palmitoyltransferase ZDHHC11B with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets